Publications by authors named "Richard Finkel"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

17,181

Total Likes

1,223

Extended Reach

2,416,314

Social Features

130
E
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children.
Swati Mummidivarpu, Utkarsh J Dang, Michael Ziemba, Yetrib Hathout, Paula R Clemens, Richard S Finkel

Steroids· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.
Crystal M Proud, Dũng Chí Vũ, Jo M Wilmshurst, Oranee Sanmaneechai, Sheffali Gulati, Richard S Finkel

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons.
Craig M McDonald, Michela Guglieri, Dragana Vučinić, Gyula Acsadi, John F Brandsema, Richard S Finkel

Ann Clin Transl Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.
Crystal M Proud, Richard S Finkel, Julie A Parsons, Riccardo Masson, John F Brandsema

J Clin Invest· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry.
Yasemin Erbaş, Laurent Servais, Perry B Shieh, Natalie L Goedeker, Megan A Waldrop, Richard S Finkel

J Neuromuscul Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.
Thomas O Crawford, Laurent Servais, Eugenio Mercuri, Heike Kölbel, Nancy Kuntz, Richard S Finkel

Expert Rev Neurother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad astra per aspera: treatment challenges and opportunities for children with spinal muscular atrophy and tracheostomy.
Yasemin Erbas, Richard S Finkel

Gene Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel CEST-Based Approach for Reliably Assessing Skeletal Muscle Oxidative Phosphorylation: OXCEST.
Ritambhar Burman, Yuxi Pang, Asim Bag, Richard S Finkel, Kirsten K Ness

Magn Reson Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence on nusinersen treatment of persons with SMA: a focused review.
Susan E Matesanz, Richard S Finkel

J Neuromuscul Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In utero therapy for spinal muscular atrophy: closer to clinical translation.
Eduardo F Tizzano, Georg Lindner, Ellie Chilcott, Richard S Finkel, Rafael J Yáñez-Muñoz

Brain· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Thomas O Crawford, Laurent Servais, Eugenio Mercuri, Heike Kölbel, Nancy Kuntz, Richard S Finkel

Lancet Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing and Implementing a Web-Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot-Marie-Tooth disease.
Kayla M D Cornett, Tim Estilow, Paula Bray, Melissa R Mandarakas, Gabrielle A Donlevy, Richard S Finkel

J Peripher Nerv Syst· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Richard S Finkel, Laurent Servais, Dmitry Vlodavets, Edmar Zanoteli, Maria Mazurkiewicz-Bełdzińska

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the "SMA NNE," a short neonatal neurological examination for newborns with spinal muscular atrophy.
Eugenio Mercuri, Giorgia Coratti, Costanza Cutrona, Roberto De Sanctis, Giulia Stanca, Richard Finkel

Eur J Pediatr· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen.
Giorgia Coratti, Francesca Bovis, Marika Pane, Amy Pasternak, Emilio Albamonte, Richard S Finkel

Eur J Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. Reply.
Richard S Finkel, Lutz Mueller, Heidemarie Kletzl

N Engl J Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current clinical applications of AAV-mediated gene therapy.
Barry J Byrne, Kevin M Flanigan, Susan E Matesanz, Richard S Finkel, Megan A Waldrop

Mol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants.
Kailee S Ward, Christopher P Ptak, Natalya Pashkova, Tiffany Grider, Tabitha A Peterson, Richard Finkel

Brain· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Charcot-Marie-Tooth disease type 1E: Clinical Natural History and Molecular Impact of Variants.
Kailee S Ward, Christopher P Ptak, Natalya Pashkova, Tiffany Grider, Tabitha A Peterson, Richard Finkel

medRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Spastic Paraplegia-Centers of Excellence Research Network (SP-CERN): Clinical Trial Readiness for Hereditary Spastic Paraplegia.
Luca Schierbaum, Vicente Quiroz, Kathryn Yang, Joshua Rong, Nicole Battaglia, Richard S Finkel

Neurol Genet· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Matthew Civitello, Annemarie Rohwer, Richard Finkel

Eur J Neurol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016.
Maria Carmela Pera, Giorgia Coratti, Marika Pane, Riccardo Masson, Valeria Ada Sansone, Richard Finkel

EClinicalMedicine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases.
Olivia Kim-McManus, Joseph G Gleeson, Laurence Mignon, Amena Smith Fine, Winston Yan, Richard Finkel

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-of-1 Studies in an Era of Precision Medicine.
Erika F Augustine, Timothy W Yu, Richard S Finkel

JAMA· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis